Tzu-Hao Li1, Yu-Sheng Chang2, Chih-Wei Liu3, Chin-Fang Su4, Hung-Cheng Tsai5, Yen-Po Tsao6, Hsien-Tzung Liao5, Ming-Han Chen5, Chih-Cheng Chuang7, Ying-Ying Yang8, Chang-Youh Tsai9. 1. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen Chang Rd., Taipei, Shihlin District 111 Taiwan; Institute of Clinical Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Faculty of Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan. 2. Institute of Biomedical Informatics, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, No. 291 Zhong-zheng Road, New Taipei City, Zhonghe District, Taiwan; Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei city, Taiwan. 3. Institute of Clinical Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Faculty of Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Taipei City, Beitou District, Taiwan. 4. Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Taipei City, Beitou District, Taiwan. Electronic address: cfsu@vghtpe.gov.tw. 5. Faculty of Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Taipei City, Beitou District, Taiwan. 6. Institute of Clinical Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Faculty of Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Taipei City, Beitou District, Taiwan. Electronic address: yptsao@vghtpe.gov.tw. 7. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen Chang Rd., Taipei, Shihlin District 111 Taiwan; School of Medicine, Fu Jen Catholic University, No.510, Zhongzheng Rd., New Taipei City, Xinzhuang District, Taiwan. Electronic address: m001005@ms.skh.org.tw. 8. Institute of Clinical Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Faculty of Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Division of Clinical Skills Training, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Taipei City, Beitou District, Taiwan; Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Taipei City, Beitou District, Taiwan. Electronic address: yangyy@vghtpe.gov.tw. 9. Faculty of Medicine, National Yang-Ming University, No.155, Sec.2, Linong St., Taipei City, Beitou District 112 Taiwan; Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Taipei City, Beitou District, Taiwan. Electronic address: cytsai@vghtpe.gov.tw.
Abstract
BACKGROUND: Sarcopenia is an ever-increasingly recognized entity in aging or chronically-ill individuals. A recent surge of researches came out on sarcopenia in rheumatoid arthritis (RA). However, the results varied widely. We tried to assess the prevalence of and associated factors with sarcopenia in patients with RA. METHODS: We searched the investigations dealing with the prevalence of and associated factors with sarcopenia in RA from PubMed, EMBASE, CENTRAL, EBSCOhost, Airiti Library, CEPS, CNKI and J-STAGE from the inception to January 11, 2020. Effects regarding prevalence and associated factors were extracted and evaluated by random-effects model. Sensitivity analysis was also performed. RESULTS: Seventeen studies containing 3,140 RA subjects were identified. After exclusion of outliers, the pooled prevalence of sarcopenia was 31%. Neither ongoing-study districts nor diagnostic modalities affected prevalence significantly. Any associated factors being mentioned in at least two publications were analyzed, yielding functional limitation (Steinbrocker stage III/IV), high CRP and RF seropositivity as the significant risk factors. Based on disease durations, we carried out meta-regression and found DAS28 and HAQ are predictive models. There was no alteration in the interpretation of results from sensitivity analysis after removal of any studies skewed in sampling distribution. CONCLUSIONS: The prevalence of sarcopenia in patients with RA is high, compared to that in general counterparts. Disease duration rather than age, residing area or diagnostic modalities influences sarcopenia development; DAS28 and HAQ predict occurrence. High index of suspicion to facilitate early detection of sarcopenia in RA patients is important.
BACKGROUND:Sarcopenia is an ever-increasingly recognized entity in aging or chronically-ill individuals. A recent surge of researches came out on sarcopenia in rheumatoid arthritis (RA). However, the results varied widely. We tried to assess the prevalence of and associated factors with sarcopenia in patients with RA. METHODS: We searched the investigations dealing with the prevalence of and associated factors with sarcopenia in RA from PubMed, EMBASE, CENTRAL, EBSCOhost, Airiti Library, CEPS, CNKI and J-STAGE from the inception to January 11, 2020. Effects regarding prevalence and associated factors were extracted and evaluated by random-effects model. Sensitivity analysis was also performed. RESULTS: Seventeen studies containing 3,140 RA subjects were identified. After exclusion of outliers, the pooled prevalence of sarcopenia was 31%. Neither ongoing-study districts nor diagnostic modalities affected prevalence significantly. Any associated factors being mentioned in at least two publications were analyzed, yielding functional limitation (Steinbrocker stage III/IV), high CRP and RF seropositivity as the significant risk factors. Based on disease durations, we carried out meta-regression and found DAS28 and HAQ are predictive models. There was no alteration in the interpretation of results from sensitivity analysis after removal of any studies skewed in sampling distribution. CONCLUSIONS: The prevalence of sarcopenia in patients with RA is high, compared to that in general counterparts. Disease duration rather than age, residing area or diagnostic modalities influences sarcopenia development; DAS28 and HAQ predict occurrence. High index of suspicion to facilitate early detection of sarcopenia in RApatients is important.
Authors: Fausto Salaffi; Marina Carotti; Andrea Di Matteo; Luca Ceccarelli; Sonia Farah; Catalina Villota-Eraso; Marco Di Carlo; Andrea Giovagnoni Journal: Radiol Med Date: 2022-09-20 Impact factor: 6.313
Authors: Roswitha Dietzel; Sabine Wiegmann; Diana Borucki; Christian Detzer; Kim Nikola Zeiner; Désirée Schaumburg; Bjoern Buehring; Frank Buttgereit; Gabriele Armbrecht Journal: RMD Open Date: 2022-09